Background. Chronic kidney disease is a growing public health problem worldwide. Previous studies have identified several predictors for renal function decline. However, these studies used a single measurement of these risk factors. Therefore, the aim of this study was to investigate whether besides the baseline values of these risk factors, changes in risk factors are associated with subsequent rate of renal function loss. Methods. Five thousand, six hundred and fifty-one participants in the Prevention of Renal and Vascular ENd-stage Disease (PREVEND) Study, a prospective, communitybased cohort study, completed three screening visits during a follow-up of 6.5 years for detailed clinical and biochemical measurements. Change in renal function between the second and third screening rounds was chosen as the study parameter of interest. Changes in risk factors between the first and second screening rounds were incorporated as potential predictors for renal function loss in multivariable linear regression analyses. Based on the results of a previous study, gender-specific analyses were performed. Results. In males, an increase in urinary albumin excretion (UAE), systolic blood pressure (SBP) and cholesterol was associated with a subsequent higher rate of renal function loss, whereas in females, increases in glucose levels were associated with an increase in renal function. For males, the analyses showed that both the baseline values and the change in UAE and cholesterol were significant predictors for increased rate of renal function loss during subsequent follow-up. With respect to SBP, when taking also the change in this variable into account, the baseline value was no longer a significant predictor for renal function loss. Conclusions. The results of the present study show the value of screening programs including repeated measurements of risk factors. Furthermore, these data indicate that, besides baseline values of risk factors, the changes over time in these factors should also be taken into account when developing 'Renal Risk Scores' to identify subjects in the general population who are at risk for accelerated renal function deterioration.
Introduction
Worldwide, awareness of the high prevalence and burden of chronic kidney disease (CKD) has increased [1] [2] [3] . There is a general feeling that subjects at risk for accelerated renal function loss should be identified as early as possible for timely start of renoprotective treatment. To detect high-risk subjects, screening programs could be a valid tool. For such screening programs, knowledge on risk factors for CKD is essential.
A community-based cohort study showed that, besides a lower baseline estimated glomerular filtration rate (eGFR), the established cardiovascular risk factors age, diabetes, body mass index and smoking were associated with a higher risk to develop chronic kidney disease [4] . Results from the Prevention of Renal and Vascular ENd-stage Disease (PRE-VEND) Study identified gender-specific predictors for renal function loss. In males, high albuminuria, glucose and systolic blood pressure were associated with accelerated renal function loss over time, whereas in females, systolic blood pressure, plasma glucose and cholesterol/HDL ratio were associated with accelerated renal function loss [5] .
The aforementioned studies used a single measurement of these risk factors at only one time point to predict the rate of renal function loss during follow-up. Knowledge on changes in these variables during follow-up may be of added value to predict renal function outcome. For instance, in patients with known renal disease, a change in albuminuria by antihypertensive, and specifically ACEi/ARB treatment or a low protein diet, is associated with better renal outcome [6] . Only a few studies have studied the impact of changes in renal risk factors on renal function outcome in the general population [7] [8] [9] [10] [11] . Of note, these studies investigated the impact of change in only one specific risk factor. Data on multivariable analyses are not yet available.
The aim of this study is to investigate whether changes in risk factors for renal function decline are associated with the rate of renal function loss during subsequent follow-up. Based on our previous results [5] , we decided to perform gender-specific analyses. For this study, we used data of subjects who participated in three screening rounds of the population-based PREVEND Study to relate changes in risk factors between the first and second screening rounds to the rate of renal function loss between the second and third screening rounds.
Materials and methods

Study design and population
The analyses are based on data of subjects who participated in the first three screening rounds of the PREVEND Study. This is a prospective, community-based cohort study, designed to investigate the impact of urinary albumin excretion (UAE) on renal and cardiovascular outcome in the general population. In 1997-98, the participants of the PREVEND cohort were selected from 40 856 inhabitants of the city of Groningen, the Netherlands. To obtain a cohort enriched for the presence of elevated albuminuria levels, selection was based on the albumin concentration in a spot morning urine sample. In this ongoing study, participants are invited to visit an outpatient for a medical examination at ∼3-year intervals. Details of the study protocol have been published elsewhere and can be found on www.PREVEND.org.
In total, 8592 participants completed the first screening round in 1997-98. Approximately 6.5 years later, from 2003 to 2006, the third screening round took place. During the interval between the first and the third screening rounds, 377 subjects died, and 2415 subjects withdrew consent (with vital status known) (Figure 1 ). Thus, 5862 subjects completed the third screening round. For the present study, we excluded subjects who at the first screening round indicated to have renal disease during the first screening round (n = 22) and subjects with incomplete information on the eGFR measurements, leaving 5651 subjects for analysis. The PREVEND Study was approved by the local medical ethics committee and conducted in accordance with the guidelines of the Declaration of Helsinki. All participants gave written informed consent.
Measurements and definitions
Each screening round consisted of two visits to an outpatient department separated by ∼3 weeks. Participants filled out a questionnaire on demographics, cardiovascular and renal history, smoking status and the use of oral antidiabetic, antihypertensive and lipid-lowering drugs. Smoking was defined as current smoking (including subjects who had quit smoking for ∼1 year before the screening) or non-smoking (including subjects who had quit smoking at least 1 year before the screening). Information on drug use was completed with data from community pharmacies, including information on class of antihypertensive medication (ACEi/ARB). At both visit days of each screening round, blood pressure was measured in the right arm, every minute for 10 and 8 minutes, respectively, by an automatic Dinamap XL Model 9300 series device (Johnson-Johnson Medical INC, Tampa, Florida). For systolic blood pressure, the mean of the last two recordings from each of the two visit days of a screening round was used. Anthropometrical measurements were performed, and fasting blood samples were taken. In addition, subjects collected urine for two consecutive periods of 24 hours. Concentrations of total cholesterol and plasma glucose were measured using standard methods. Serum creatinine was measured by dry chemistry (Eastman Kodak, Rochester, New York, USA), with intra-assay coefficient of variation of 0.9% and interassay coefficient of variation of 2.9%. To avoid changes over time in creatinine measurements, we have a strict protocol with constant quality control. eGFR was estimated using the Modification of Diet in Renal Disease (MDRD) study equation, taking into account gender, age, race and serum creatinine [12] . Urinary albumin concentration was determined by nephelometry (Dade Behring Diagnostic, Marburg, Germany), and UAE was given as the mean of the two 24-hour urinary excretions. Changes in UAE, SBP, glucose, cholesterol and waist circumference between the first and the second screenings were calculated and expressed per year of follow-up. Changes in smoking habits were based on the questionnaires and changes in the use of ACEi/ARB, and other antihypertensive medication was based on the pharmacy data. The change in subsequent eGFR was calculated between the second and third screening rounds and also expressed per year of follow-up.
Statistical analyses
Continuous data were reported as mean and standard deviation. For skewed distributions, median and interquartile range were presented. All P-values were two-tailed. A P-value <0.05 was considered statistically significant. Baseline characteristics of our study population were shown for males and females separate.
For our analyses, we used the following known modifiable cardiovascular risk factors for our analyses; UAE, SBP, plasma glucose, cholesterol, waist circumference, smoking and use of ACEi/A2A medication and oth- Change in risk factors vs renal function outcomeer antihypertensive medication. For blood pressure, we also analysed other measurements than SBP (diastolic blood pressure, mean arterial pressure and pulse pressure). The results for the different blood pressure measurement were comparable. We chose to use SBP as this variable is most widely used in related articles. To avoid colinearity in the multivariable models, only one blood pressure measure was implemented. Since a previous analysis showed gender-specific risk factors for renal function outcome, it was decided a priori to perform all analyses for males and females separately [5] . To study the impact of changes in risk factors on the subsequent rate of renal function loss, linear regression analyses were used. The change in eGFR was analysed as a continuous variable; therefore, we investigated a large range of eGFR changes including both normal age-related changes and abnormal pathological changes in eGFR. Changes in risk factors between the first and second screening rounds were used as determinant, and changes in eGFR between the second and third screening rounds were used as outcome variable ( Figure 1 ) after initial univariate linear regression analyses. Secondly, we corrected our analyses for age, eGFR and baseline value of the risk factor. We corrected the models for eGFR to reduce the effect of regression to the mean. Finally, we performed forward multivariable regression analyses. To adjust for the enrichment of our study cohort with subjects with higher levels of albuminuria, all analyses were weighted. All models were tested for possible non-linear associations between the changes in the risk factors under investigation and subsequent rate of renal function loss. This was tested by adding quadratic terms to the multivariable regression model. Quadratic terms with a P-value <0.05 were considered significant. We tested for possible effect modification by means of interaction terms. Lastly, graphical representations were made of the associations between the changes in the most important predictors and the rate of renal function loss during subsequent follow-up. For females, we repeated the analyses including only postmenopausal females to investigate the role of hormonal status. We also performed all analyses with IDMS-traceable serum creatinine values. A correction factor was used to obtain serum creatinine values that are IDMS-traceable. The appropriate MDRD equation was used = only subjects with the required data available are included in the analyses. A negative beta indicates that an increase in that risk factor between the first and second screenings was associated with a higher rate of eGFR loss between the second and third screenings. For instance, in males, an increase in UAE was associated with more renal function loss during follow-up.
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[13] for this sensitivity analysis. All analyses were conducted with the use of the statistical package SPSS 14.0 (SPSS, Chicago, IL).
Results
The mean (± SD) period between the first and second screenings was 4.2 ± 0.42 years and between the second and third screenings 2.2 ± 0.34 years. The changes in eGFR in these periods were −0.53 and −0.23 mL/min/ 1.73m 2 per year follow-up, respectively. Baseline characteristics of the study cohort including the changes in risk factors (between first and second screening rounds expressed per year follow-up) are given in Table 1 for males and females, separately. The baseline characteristics of the subjects who completed all three screening rounds were comparable with the subjects who did not, concerning age (48.2 vs 48.7 years), SBP (127 vs 125 mmHg), glucose (4.7 vs 4.7 mmol/L), cholesterol (5.6 vs 5.6 mmol/L), UAE (7.0 vs 7.0 mg/24 hours), waist (86.9 vs 86.9 cm) and eGFR (80.6 vs 80.3 ml/min/1.73m
2 ). Among the non-responders, only the percentage smokers (42% vs 32%) and use of ACEi medication (3.8% vs 3.0%) were different from responders.
At baseline, the levels for serum creatinine and eGFR for the total population were 84.7 μmol/L and 78.6 mL/ min/1.73 m 2 , and for different age groups, 82.3 μmol/L and 84. Table 2 shows the results of the univariate linear regression analyses and the results of the adjustment for age, eGFR and baseline values of the risk factor under investigation. The results of the univariate analyses showed associations between an increase in UAE, SBP and cholesterol in males and an increased rate of renal function loss during subsequent follow-up. In females, an increase in plasma glucose was associated with a subsequent increase in eGFR. Also after adjustment, in males, increases in UAE and cholesterol were significantly associated with an increased rate of renal function loss during subsequent follow-up, whereas in females, an increase in plasma glucose was associated with an increase in renal function. Changes in the use of ACEi/ARB medication, antihypertensive medication or smoking habits were not associated with subsequent rates of renal function loss. Tables 3 and 4 present the results of the final genderspecific multivariable linear regression models. The first two columns of Tables 3 and 4 present gender-specific multivariable linear regression models only including the baseline values of the risk factors. The last two columns show the models including also the changes in these risk factors. The first columns of Table 3 show that a higher baseline value of SBP, cholesterol and UAE were associated with a subsequent increased rate of renal function loss. The final model showed that an increase in SBP was significantly associated with a subsequent increased rate of renal function loss, whereas the baseline value of SBP was no longer significant. This implies that a change in SBP is a better predictor compared with the respective baseline value. For UAE and cholesterol applies that both the baseline values and the changes in these factors were significantly associated with a subsequent increased rate of renal function loss. Of note, the associations between changes in SBP and cholesterol were non-linear; therefore, quadratic terms were added to the models. For changes in UAE and SBP, as well as cholesterol, this means that increases in these risk factors were associated with a subsequent increased rate of renal function loss (see also Figure  2 ). In females, the first model (Table 4) showed that a higher baseline SBP and UAE were significant predictors for a subsequent increased rate of renal function loss. In the final model, a change in plasma glucose was positively associated with the subsequent change in renal function. Figure 2 presents the graphical interpretation of the associations between the change in risk factors between the first and second screenings and the subsequent rate of renal function loss between the second and third screening rounds. The histograms in this figure represent the distribution of the changes in risk factors for this population. The results of the subgroup analyses performed in postmenopausal women were comparable with the analyses performed in all females (data not shown). The sensitivity analysis using IDMS-traceable serum creatinine values showed essentially similar results.
Discussion
In this study, we investigated in a community-based study cohort whether, besides baseline risk factors, changes in risk factors are associated with the rate of renal function loss during subsequent follow-up. We found that, in males, an increase in UAE, SBP and cholesterol were associated with subsequent rate of renal function loss, whereas in females, increases in plasma glucose levels were associated with an increase in renal function. For males, the results showed that both the baseline values and the change in UAE and cholesterol were predictors for increased rate of renal function loss during subsequent follow-up. However, when taking also the change in SBP into account the baseline value of SBP was no longer significant.
Information about the effect of changes in risk factors on renal function course is limited. In this study, increases in UAE were associated with a subsequent increased rate of renal function loss in males, but in females, this association was absent. A previous study, also performed in the PRE-VEND population, showed that, only in males, a high UAE was a risk factor for an increased rate of renal function loss independent of other cardiovascular risk factors [5] .
In males, increased SBP was also associated with a subsequent increased rate of renal function loss. Furthermore, our data indicate that an increase in SBP is a better predictor for a subsequent increased rate of renal function loss than baseline SBP. This is partly in line with another small study, which showed that both an increase in SBP and the baseline value of SBP were associated with an increased rate of renal function loss. In this small study, no gender differences were reported [10] . Increases in SBP were also associated with a subsequent increased rate of renal function loss in a study in treated hypertensive males with multiple measures of eGFR and SBP available [11] .
Our analyses showed that, in males, increases in total cholesterol were associated with a subsequent increased rate of renal function loss. Literature on the effect of changes in total cholesterol in cohort studies is lacking. However, most literature on the effect of baseline total cholesterol suggests that high baseline total cholesterol is a predictor for renal function decline [14, 15] .
In females, we found a positive association between increases in glucose and subsequent increases in eGFR. This increase in eGFR induced by hyperglycaemia could reflect hyperfiltration. Hyperfiltration is generally seen as an early stage in the pathophysiology of renal disease progression [16] . Taking this into account, we expect to find an increased rate of renal function loss in females after a lon- eGFR estimated glomerular filtration rate; SBP systolic blood pressure; Ln_UAE natural logarithm of urinary albumin excretion. NS = not significant. Fig. 2 . Relationship between changes in predictors under investigation and the subsequent change in eGFR (ml/min/1.73m 2 /year) (left axis) in univariate models for males (left) and for women (right). The Loess method (locally weighted polynomial regression analysis) [24] is used to plot these associations. Histograms represent the percentage of the population (right axis) at a given change in predictor. Abbreviations are eGFR: estimated glomerular filtration rate, SBP: systolic blood pressure, UAE: urinary albumin excretion ger period of follow-up. A gender difference in the effect of an increase in glucose is in line with another study performed in type 1 diabetic patients. In this study, induced hyperglycaemia caused an increase in eGFR in females, whereas in males, this increase in eGFR was lacking [17] .
Starting or cessation of smoking was not associated with changes in renal function afterwards. A number of studies reported a negative effect of smoking on rate of renal function decline [18] [19] [20] . However, there is only little information concerning the effect of smoking cessation on the course of renal function. A few studies suggested that smoking cessation slows the rate of renal function decline and/or lowers the risk of developing chronic kidney disease compared with current smokers [7] [8] [9] . Recently, Phisitkul et al. showed that smoking cessation in subjects with diabetic nephropathy slows down renal function loss [9] . Another study, performed in a population-based cohort, showed that the positive effect of smoking cessation is associated with the number of years stopped smoking. The age-and sex-adjusted odds ratios for developing chronic kidney disease were 1.05 for the subjects who stopped >5 years and 3.93 for subjects stopped <5 years (>15 years stopped is used as reference category) [7] . According to these results, our relative short follow-up could be the reason why we did not find an effect of smoking cessation.
Changes in the use of ACEi/ARB medication did not influence the subsequent rate of renal function loss. Possible explanations for these results could be confounding by indication [21] , the short-term haemodynamic effects of ACEi/ARB medication (lowering of intraglomerular pressure and therefore a slight decrease in GFR) or a lack of power. Of note, for the analyses concerning cessation, the use of ACEi/ARB medication only 229 subjects were available and only 54 subjects stopped using ACEi/ARB between the first and second screenings.
Strengths of this study are the use of a large prospective community-based cohort, the availability of data of three subsequent screening rounds and detailed information on many covariates. The PREVEND Study is enriched for higher levels of albuminuria. Therefore, weighted analyses are performed, and this did not influence the results. Some limitations should be mentioned. The PREVEND Study is selected from a predominantly Caucasian population. Therefore, our findings cannot simply be generalized to other populations. Of note, an earlier study performed with the PREVEND data showed that the design of the study did not lead to more drug prescription compared with a random selected unscreened population. Therefore, the changes in treatment reflect the normal population [22] . The followup for renal function between the second and the third screenings is relatively short (2.2 years) and may be too short to identify all potential risk factors. Previously, we found gender-specific predictors for renal function decline, and in the present analyses, we identified interactions between gender and several predictors. Based on these results, we believe that there is a true gender effect. However, these epidemiological studies offer information about these associations but we need more fundamental research to explain the biological pathways causing these gender differences.
What are the consequences of these findings? The burden of chronic kidney disease on the public health-care system is increasing, and prevention of CKD is therefore a global challenge [23] . For prevention, early identification of subjects at risk for increased rate of renal function loss is essential. This might be achievable by development of risk prediction equations. Identified risk factors for increased rate of renal function loss could be implemented in such a risk prediction equation. This study shows that, in a 'Renal Risk Score', not only baseline values but also changes in risk factors could be useful to identify subjects in the general population at risk of renal function decline, who may benefit from early intervention. However, 'Renal risk scores' used in large populations should be as simple as possible, and therefore, only baseline values will be included. In smaller high risk populations, including changes in risk factors in risk scores should be considered.
In conclusion, this study shows that, in males, increases in UAE, SBP and cholesterol are predictors for subsequent increased rate of renal function loss, independent of the baseline values of these known cardiovascular risk factors, whereas in females, an increase in glucose was a significant predictor for hyperfiltration. These findings emphasize the value of screening programs including repeated measurements of the known risk factors for accelerated renal function decline.
